The FDA has fast tracked the review of psychedelic treatments, including psilocybin and a methylone compound similar to MDMA, for depression and PTSD. The move reflects growing urgency around the mental health crisis, particularly among veterans, with a potential approval as early as this summer. These therapies aim to help patients process trauma more deeply, often alongside psychotherapy. However, approval remains uncertain, as past rejections have raised concerns about safety and evidence. Read more here.